Table 2.

Hormone receptor and HER2 receptor status by stage at presentation for investigated breast cancer categories^a

	Inflammatory breast cancer		Locally advanced breast cancer	Metastatic breast cancer	Non-T4 breast cancer
	Stage IIIB	Stage IV	Stage IIIB	Stage IV	Stage I	Stage IIA	Stage IIB	Stage IIIA	Stage IIIB
Estrogen receptor status
Estrogen receptor-negative	536 (45%)	139 (40%)	319 (33%)	573 (27%)	4,836 (15%)	4,323 (24%)	2,510 (26%)	730 (32%)	20 (36%)
Estrogen receptor-positive	655 (55%)	207 (60%)	653 (67%)	1,533 (73%)	27,491 (85%)	13,778 (76%)	7,091 (74%)	1,565 (68%)	35 (64%)
Number missing	329	148	296	953	6244	3,207	1,536	380	12
Progesterone receptor status
Progesterone receptor-negative	640 (55%)	179 (55%)	430 (46%)	826 (42%)	8,482 (28%)	6,166 (35%)	3,495 (38%)	973 (44%)	21 (41%)
Progesterone receptor-positive	517 (45%)	149 (45%)	511 (54%)	1,123 (58%)	22,326 (72%)	11,222 (65%)	5,748 (62%)	1,229 (56%)	30 (59%)
Number missing	363	166	327	1,110	7,763	3,920	1,894	473	16
Hormone receptor status
Hormone receptor-negative	502 (42%)	124 (36%)	303 (31%)	533 (25%)	4,426 (14%)	4,021 (22%)	2,351 (24%)	683 (30%)	18 (33%)
Hormone receptor-positive	694 (58%)	222 (53%)	671 (69%)	1,578 (75%)	28,003 (86%)	14,138 (78%)	7,267 (76%)	1,617 (70%)	37 (67%)
Number missing	324	148	294	948	6,142	3,149	1,519	375	12
HER2 receptor status
HER2-negative	556 (60%)	147 (57%)	484 (65%)	942 (65%)	18,280 (82%)	10,110 (77%)	5,104 (72%)	1,235 (70%)	25 (64%)
HER2-positive	367 (40%)	110 (43%)	255 (35%)	506 (35%)	4,058 (18%)	2,953 (23%)	2,010 (28%)	540 (30%)	14 (36%)
Number missing	597	237	529	1,611	16,233	8,245	4,023	900	28

^aCalifornia Cancer Registry data, 1999 to 2004. HER2, human epidermal growth factor-like receptor 2.